Brokerages Expect Cardlytics Inc (NASDAQ:CDLX) to Announce -$0.15 EPS

Equities analysts expect that Cardlytics Inc (NASDAQ:CDLX) will report earnings of ($0.15) per share for the current quarter, according to Zacks. Five analysts have issued estimates for Cardlytics’ earnings. The lowest EPS estimate is ($0.24) and the highest is ($0.10). Cardlytics also posted earnings per share of ($0.15) during the same quarter last year. The firm is scheduled to announce its next quarterly earnings report after the market closes on Tuesday, November 12th.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

On average, analysts expect that Cardlytics will report full-year earnings of ($0.62) per share for the current financial year, with EPS estimates ranging from ($0.80) to ($0.49). For the next financial year, analysts expect that the company will report earnings of ($0.14) per share, with EPS estimates ranging from ($0.39) to $0.25. Zacks Investment Research’s EPS averages are a mean average based on a survey of analysts that that provide coverage for Cardlytics.

Cardlytics (NASDAQ:CDLX) last announced its earnings results on Thursday, August 8th. The company reported ($0.12) earnings per share for the quarter, beating the consensus estimate of ($0.35) by $0.23. Cardlytics had a negative return on equity of 66.01% and a negative net margin of 19.60%. The company had revenue of $48.73 million for the quarter, compared to the consensus estimate of $43.77 million. During the same period last year, the business posted ($0.21) EPS. The company’s revenue was up 37.0% on a year-over-year basis.

Several equities analysts recently commented on the company. Zacks Investment Research lowered Cardlytics from a “buy” rating to a “hold” rating in a research note on Thursday, October 31st. SunTrust Banks upped their target price on Cardlytics from $25.00 to $35.00 and gave the company a “buy” rating in a research note on Friday, August 9th. Raymond James upped their target price on Cardlytics from $24.00 to $40.00 and gave the company an “outperform” rating in a research note on Friday, August 9th. JPMorgan Chase & Co. set a $43.00 target price on Cardlytics and gave the company a “buy” rating in a research note on Friday, August 9th. Finally, ValuEngine lowered Cardlytics from a “hold” rating to a “sell” rating in a research note on Wednesday, October 2nd. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have given a buy rating to the company’s stock. Cardlytics presently has an average rating of “Buy” and a consensus price target of $34.86.

In other Cardlytics news, CFO David Thomas Evans sold 5,000 shares of the business’s stock in a transaction dated Friday, November 1st. The stock was sold at an average price of $40.98, for a total transaction of $204,900.00. Also, Director Tony Weisman sold 33,484 shares of the company’s stock in a transaction dated Monday, August 12th. The stock was sold at an average price of $31.36, for a total value of $1,050,058.24. The disclosure for this sale can be found here. In the last three months, insiders have acquired 316,475 shares of company stock valued at $11,914,849 and have sold 2,649,922 shares valued at $83,318,325. 21.90% of the stock is currently owned by insiders.

Several hedge funds and other institutional investors have recently modified their holdings of CDLX. BlackRock Inc. boosted its position in shares of Cardlytics by 94.2% in the second quarter. BlackRock Inc. now owns 903,619 shares of the company’s stock worth $23,476,000 after buying an additional 438,215 shares during the period. Grantham Mayo Van Otterloo & Co. LLC purchased a new stake in shares of Cardlytics in the second quarter worth about $10,392,000. Vanguard Group Inc. boosted its position in shares of Cardlytics by 46.1% in the second quarter. Vanguard Group Inc. now owns 755,132 shares of the company’s stock worth $19,618,000 after buying an additional 238,211 shares during the period. Antipodean Advisors LLC purchased a new stake in shares of Cardlytics in the second quarter worth about $3,698,000. Finally, JPMorgan Chase & Co. boosted its position in shares of Cardlytics by 177.9% in the second quarter. JPMorgan Chase & Co. now owns 199,301 shares of the company’s stock worth $4,901,000 after buying an additional 127,596 shares during the period. 79.61% of the stock is owned by institutional investors.

Shares of CDLX stock traded up $0.01 during midday trading on Friday, hitting $40.01. The company had a trading volume of 308,900 shares, compared to its average volume of 312,529. The stock has a market cap of $928.40 million, a price-to-earnings ratio of -18.70 and a beta of 1.56. The company’s 50 day simple moving average is $36.89 and its 200 day simple moving average is $29.43. Cardlytics has a 52-week low of $9.80 and a 52-week high of $42.19. The company has a debt-to-equity ratio of 0.79, a current ratio of 2.01 and a quick ratio of 2.01.

Cardlytics Company Profile

Cardlytics, Inc operates a purchase intelligence platform in the United States and the United Kingdom. It operates in two segments, Cardlytics Direct and Other Platform Solutions. The company's platform is the Cardlytics Direct solution, a proprietary native bank advertising channel that enables marketers to reach consumers through their trusted and frequently visited online and mobile banking channels.

Featured Story: How to read a candlestick chart

Get a free copy of the Zacks research report on Cardlytics (CDLX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Cardlytics (NASDAQ:CDLX)

Leave a Reply

Your email address will not be published. Required fields are marked *

*